Stocks and Investing
Stocks and Investing
Mon, March 6, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Patrick Trucchio Maintained (VIR) at Strong Buy with Decreased Target to $100 on, Mar 6th, 2023
Patrick Trucchio of HC Wainwright & Co., Maintained "Vir Biotechnology, Inc." (VIR) at Strong Buy with Decreased Target from $125 to $100 on, Mar 6th, 2023.
Patrick has made no other calls on VIR in the last 4 months.
There are 4 other peers that have a rating on VIR. Out of the 4 peers that are also analyzing VIR, 1 agrees with Patrick's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Upgraded from Sell to Hold and Increased Target to $30 on, Friday, January 27th, 2023
These are the ratings of the 3 analyists that currently disagree with Patrick
- Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $32 on, Friday, February 24th, 2023
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $53 on, Thursday, February 23rd, 2023
- Roanna Ruiz of "SVB Leerink" Maintained at Buy with Decreased Target to $43 on, Friday, January 27th, 2023
Contributing Sources